Drugs / SGS742
SGS742
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02019667 | Mar 2014 → Jan 2019 | epilepsy, metabolic disease | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | Missed primary |
| Phase 2 | NCT00093951 | Apr 2004 → Sep 2007 | Alzheimer disease | Saegis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SGS742 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00093951 ↗ |
| Known as | CGP-36742 | ChEMBL registry synonym — accepted as the source's own label CHEMBL112797 ↗ |
| Known as | LU-AE-58479 | ChEMBL registry synonym — accepted as the source's own label CHEMBL112797 ↗ |
| Action | Inhibit | “GABA(B) receptor antagonist” NCT00093951 ↗ |
| Modality | Small molecule | — CHEMBL112797 ↗ |
| Route | Oral | “It is an orally active drug” NCT00093951 ↗ |